On Monday, the GlaxoSmithKline PLC and Canadian partner Valeant Pharmaceuticals International Inc. had announced to receive an approval from the U. S. drug regulators for their epilepsy pill Potiga, as an add-on treatment for partial onset seizures, which begins in one side of the brain.

Valeant Pharmaceuticals International Inc. is Canada’s largest drug maker. The company has announced that it has made a hostile bid of $5.7 billion to acquire Cephalon Inc. or $73 a share in cash.

NYSE-listed Valeant Pharmaceuticals International has reported that it has completed the acquisition of Dow Pharmaceutical Sciences, Inc., a privately held dermatology company that specializes in the development of topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.

Valeant Pharmaceuticals International has signed a definitive agreement to acquire Dow Pharmaceutical Sciences, Inc., a privately held company that specializes in the development of topical drug products for pharmaceutical and biotechnology clients.